Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 144.60
FLML's Cash to Debt is ranked higher than
53% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. FLML: 144.60 )
Ranked among companies with meaningful Cash to Debt only.
FLML' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 13.65 Max: N/A
Current: 144.6
Equity to Asset 0.21
FLML's Equity to Asset is ranked lower than
87% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. FLML: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
FLML' s Equity to Asset Range Over the Past 10 Years
Min: -0.13  Med: 0.53 Max: 0.8
Current: 0.21
-0.13
0.8
Interest Coverage 11.00
FLML's Interest Coverage is ranked lower than
86% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. FLML: 11.00 )
Ranked among companies with meaningful Interest Coverage only.
FLML' s Interest Coverage Range Over the Past 10 Years
Min: 11  Med: 11.34 Max: 11.34
Current: 11
11
11.34
F-Score: 7
Z-Score: 2.00
M-Score: -0.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 34.03
FLML's Operating margin (%) is ranked higher than
93% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. FLML: 34.03 )
Ranked among companies with meaningful Operating margin (%) only.
FLML' s Operating margin (%) Range Over the Past 10 Years
Min: -1285  Med: -72.79 Max: 41.25
Current: 34.03
-1285
41.25
Net-margin (%) 12.11
FLML's Net-margin (%) is ranked higher than
83% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. FLML: 12.11 )
Ranked among companies with meaningful Net-margin (%) only.
FLML' s Net-margin (%) Range Over the Past 10 Years
Min: -1027.16  Med: -37.07 Max: 23.47
Current: 12.11
-1027.16
23.47
ROE (%) 49.44
FLML's ROE (%) is ranked higher than
98% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. FLML: 49.44 )
Ranked among companies with meaningful ROE (%) only.
FLML' s ROE (%) Range Over the Past 10 Years
Min: -1103.89  Med: -25.52 Max: 87.66
Current: 49.44
-1103.89
87.66
ROA (%) 11.08
FLML's ROA (%) is ranked higher than
92% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. FLML: 11.08 )
Ranked among companies with meaningful ROA (%) only.
FLML' s ROA (%) Range Over the Past 10 Years
Min: -58.46  Med: -12.4 Max: 20.89
Current: 11.08
-58.46
20.89
ROC (Joel Greenblatt) (%) 2417.05
FLML's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. FLML: 2417.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
FLML' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1730.55  Med: -42.79 Max: 3856.65
Current: 2417.05
-1730.55
3856.65
Revenue Growth (3Y)(%) 136.60
FLML's Revenue Growth (3Y)(%) is ranked higher than
95% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. FLML: 136.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
FLML' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.4  Med: -0.1 Max: 136.6
Current: 136.6
-52.4
136.6
» FLML's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

FLML Guru Trades in Q2 2015

Steven Cohen Sold Out
» More
Q4 2015

FLML Guru Trades in Q4 2015

Steven Cohen 67,012 sh (New)
» More
Q1 2016

FLML Guru Trades in Q1 2016

Steven Cohen 358,958 sh (+435.66%)
» More
Q2 2016

FLML Guru Trades in Q2 2016

Steven Cohen 461,839 sh (+28.66%)
» More
» Details

Insider Trades

Latest Guru Trades with FLML

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CTMX, NAS:PDLI, NAS:EPZM, NAS:BLCM, NAS:KERX, NAS:ATRA, NAS:ARDX, NAS:LOXO, NAS:AMRN, NAS:MCRB, NAS:AGEN, NAS:OTIC, NAS:ACRS, NAS:EDIT, NAS:VTAE, NAS:ARRY, NAS:NVAX, NAS:RETA, NAS:NTLA, NAS:ADAP » details
Traded in other countries:FL3.Germany,
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in drug delivery and formulation to develop safer and more efficacious pharmaceutical products to address unmet medical needs and reduce overall healthcare costs.

Flamel Technologies SA was incorporated as a Societe Anonyme or SA, a form of corporation under the laws of the Republic of France in August 1990 as Flamel Technologies S.A. The Company is a specialty pharmaceutical company with a history in drug delivery, working on the development of safer and more efficacious formulations. The acquisition of Éclat on March 13, 2012 has created a more vertically integrated company, benefiting from greater development and commercial expertise and more near-term and mid-term potential value creating catalysts. Since its acquisition of Eclat, Flamel is now engaged in not only on the development and licensing of versatile, proprietary drug delivery platforms but also on the development of novel, high-value products based on those delivery platforms. Bloxiverz, the Company first NDA approval from the portfolio of Eclat products acquired in March 2012. Bloxiverz's NDA was filed in August 2012 and approved by the FDA on May 2013. The launch of Bloxiverz commenced in July 2013. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Bloxiverz is the first and only FDA-approved version of neostigmine methylsulfate, even though other versions of neostigmine have been on the market as unapproved, grandfathered products under the Food, Drug and Cosmetic Act of 1938. Coreg CR, the lead product using its Micropump drug delivery platform. Coreg CR is an extended-release formulation once-a-day of Coreg a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors. The Company faces competition from Actavis, Alkermes, BioAlliance Pharma, Depomed, Ethypharm, Octoplus, Veloxis Pharmaceuticals, Nektar Therapeutics. The Company owns and develops drug delivery platforms that are able to tackle key challenges in the formulation, in various dosage forms of a broad range of drugs novel, already-marketed, or off-patent that includes Micropump. During the 2013 the Company has 395 patents in total. The design, testing, manufacturing and marketing of certain new or substantially modified drugs, biological products or medical devices must be approved, cleared or certified by regulatory agencies, regulatory authorities and Notified Bodies under applicable laws and regulations, the requirements of which may vary from country to country.

Ratios

vs
industry
vs
history
P/E(ttm) 29.67
FLML's P/E(ttm) is ranked lower than
53% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. FLML: 29.67 )
Ranked among companies with meaningful P/E(ttm) only.
FLML' s P/E(ttm) Range Over the Past 10 Years
Min: 9.73  Med: 21.22 Max: 32.16
Current: 29.67
9.73
32.16
Forward P/E 21.14
FLML's Forward P/E is ranked lower than
58% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. FLML: 21.14 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.67
FLML's PE(NRI) is ranked lower than
53% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. FLML: 29.67 )
Ranked among companies with meaningful PE(NRI) only.
FLML' s PE(NRI) Range Over the Past 10 Years
Min: 9.73  Med: 21.22 Max: 32.16
Current: 29.67
9.73
32.16
Price/Owner Earnings (ttm) 31.06
FLML's Price/Owner Earnings (ttm) is ranked higher than
51% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. FLML: 31.06 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
FLML' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.47  Med: 32.43 Max: 537.22
Current: 31.06
8.47
537.22
P/B 10.63
FLML's P/B is ranked lower than
84% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. FLML: 10.63 )
Ranked among companies with meaningful P/B only.
FLML' s P/B Range Over the Past 10 Years
Min: 1.84  Med: 5.04 Max: 71.87
Current: 10.63
1.84
71.87
P/S 3.36
FLML's P/S is ranked higher than
78% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. FLML: 3.36 )
Ranked among companies with meaningful P/S only.
FLML' s P/S Range Over the Past 10 Years
Min: 2.05  Med: 6.04 Max: 843.89
Current: 3.36
2.05
843.89
PFCF 36.39
FLML's PFCF is ranked lower than
63% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. FLML: 36.39 )
Ranked among companies with meaningful PFCF only.
FLML' s PFCF Range Over the Past 10 Years
Min: 9.83  Med: 25.89 Max: 154.15
Current: 36.39
9.83
154.15
POCF 34.52
FLML's POCF is ranked lower than
66% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. FLML: 34.52 )
Ranked among companies with meaningful POCF only.
FLML' s POCF Range Over the Past 10 Years
Min: 9.66  Med: 23.43 Max: 51.48
Current: 34.52
9.66
51.48
EV-to-EBIT 6.90
FLML's EV-to-EBIT is ranked higher than
81% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. FLML: 6.90 )
Ranked among companies with meaningful EV-to-EBIT only.
FLML' s EV-to-EBIT Range Over the Past 10 Years
Min: -88.3  Med: -10.8 Max: 7.7
Current: 6.9
-88.3
7.7
EV-to-EBITDA 5.56
FLML's EV-to-EBITDA is ranked higher than
82% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. FLML: 5.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
FLML' s EV-to-EBITDA Range Over the Past 10 Years
Min: -314.7  Med: -12.55 Max: 76.3
Current: 5.56
-314.7
76.3
Current Ratio 3.05
FLML's Current Ratio is ranked lower than
63% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. FLML: 3.05 )
Ranked among companies with meaningful Current Ratio only.
FLML' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 2.78 Max: 6.76
Current: 3.05
0.83
6.76
Quick Ratio 2.99
FLML's Quick Ratio is ranked lower than
61% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. FLML: 2.99 )
Ranked among companies with meaningful Quick Ratio only.
FLML' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.73 Max: 6.7
Current: 2.99
0.77
6.7
Days Inventory 107.24
FLML's Days Inventory is ranked higher than
58% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. FLML: 107.24 )
Ranked among companies with meaningful Days Inventory only.
FLML' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 100.82 Max: 1457.72
Current: 107.24
51.05
1457.72
Days Sales Outstanding 20.89
FLML's Days Sales Outstanding is ranked higher than
82% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. FLML: 20.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLML' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.7  Med: 74.39 Max: 541.87
Current: 20.89
14.7
541.87
Days Payable 200.26
FLML's Days Payable is ranked higher than
83% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. FLML: 200.26 )
Ranked among companies with meaningful Days Payable only.
FLML' s Days Payable Range Over the Past 10 Years
Min: 180.56  Med: 306.97 Max: 3311.63
Current: 200.26
180.56
3311.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.20
FLML's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. FLML: -18.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FLML' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.2  Med: -7.8 Max: -0.5
Current: -18.2
-18.2
-0.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 133.60
FLML's Price/Tangible Book is ranked lower than
99% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. FLML: 133.60 )
Ranked among companies with meaningful Price/Tangible Book only.
FLML' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.39  Med: 4.8 Max: 143.13
Current: 133.6
1.39
143.13
Price/Projected FCF 95.43
FLML's Price/Projected FCF is ranked lower than
98% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. FLML: 95.43 )
Ranked among companies with meaningful Price/Projected FCF only.
FLML' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.16  Med: 8.5 Max: 98.14
Current: 95.43
5.16
98.14
Price/Median PS Value 0.56
FLML's Price/Median PS Value is ranked higher than
78% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. FLML: 0.56 )
Ranked among companies with meaningful Price/Median PS Value only.
FLML' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 0.98 Max: 136.36
Current: 0.56
0.25
136.36
Price/Graham Number 13.49
FLML's Price/Graham Number is ranked lower than
96% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. FLML: 13.49 )
Ranked among companies with meaningful Price/Graham Number only.
FLML' s Price/Graham Number Range Over the Past 10 Years
Min: 1.98  Med: 4.05 Max: 15
Current: 13.49
1.98
15
Earnings Yield (Greenblatt) (%) 14.45
FLML's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. FLML: 14.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FLML' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 13  Med: 21.7 Max: 34.4
Current: 14.45
13
34.4

More Statistics

Revenue (TTM) (Mil) $165.8
EPS (TTM) $ 0.45
Beta1.39
Short Percentage of Float1.22%
52-Week Range $7.56 - 20.98
Shares Outstanding (Mil)41.24

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 145 176 189
EPS ($) -0.18 0.65 0.80
EPS w/o NRI ($) -0.18 0.65 0.80
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for FLML

Headlines

Articles On GuruFocus.com

More From Other Websites
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 26 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 20 2016
Flamel Technologies to Present at Ladenburg Thalmann 2016 Healthcare Conference Sep 19 2016
Flamel Technologies to Host Investor & Analyst Meeting Sep 19 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 01 2016
Flamel Technologies Hires Vice President of Sales Aug 31 2016
FLAMEL TECHNOLOGIES SA Financials Aug 23 2016
One REIT and Three Healthcare Companies See Insiders Buying and Selling Stock Aug 23 2016
ETF’s with exposure to Flamel Technologies SA : August 18, 2016 Aug 18 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Aug 16 2016
FLAMEL TECHNOLOGIES SA Files SEC form 10-Q, Quarterly Report Aug 15 2016
FLAMEL TECHNOLOGIES SA Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Aug 12 2016
Flamel Technologies SA :FLML-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Flamel Technologies Launches Akovaz(TM) Aug 12 2016
Flamel Technologies Announces Shareholder Approval of Cross-Border Merger Aug 12 2016
Edited Transcript of FLML earnings conference call or presentation 8-Aug-16 2:00pm GMT Aug 08 2016
Flamel reports 2Q loss Aug 08 2016
Flamel reports 2Q loss Aug 08 2016
Flamel Technologies Reports Second Quarter 2016 Results Aug 08 2016
Half Year 2016 Flamel Technologies SA Earnings Release - Before Market Open Aug 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)